While genomics may be inching toward the clinic, from a business perspective, the research end-market remains the prime target for most entrepreneurs in the space, writes Art Wuster at his Sequenomics blog.

Wuster looked at 72 firms listed on the technology company database Crunchbase, all of which received at least some third-party funding, and found that 38 were companies with customers in research laboratories or in other genomic firms.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Related Posts

In PNAS this week: ancestry and admixture in Brazilians, characterization of novel double-stranded RNA mycovirus, and more.

Researchers report that what scents someone picks up can reflect their complement of immune genes.

The New York Times examines ethics and China's push to lead biomedical research.

At her blog, Sally Rockey dives into National Institutes of Health funding data.